Delayed pneumothorax after CT-guided percutaneous fine needle aspiration lung biopsy

Zoë C Traill, Fergus V Gleeson

Abstract
Two patients are described who developed pneumothoraces more than 24 hours after computed tomography (CT) guided percutaneous fine needle aspiration lung biopsies. The pneumothoraces required treatment in both cases. Such delayed pneumothorax after lung biopsy is extremely unusual. Patients should be warned of the possible occurrence of this complication and instructed to seek medical help if they develop chest pain or breathlessness.

Keywords: complications, lung biopsy, pneumothorax.

Percutaneous fine needle aspiration biopsy is a well established method for diagnosing lung lesions.1-3 Although generally a safe and well tolerated procedure, pneumothorax is a relatively common and potentially serious complication.4,5 We describe two patients who developed significant pneumothoraces more than 24 hours after percutaneous fine needle aspiration lung biopsy.

Case reports

CASE 1
A 56 year old woman presented with a one month history of right sided Jacksonian-type seizures. She was a life long smoker with no past medical history of note. Physical examination was unremarkable. A computed tomographic (CT) scan of the brain revealed a single enhancing lesion in the left hemisphere with surrounding oedema in keeping with a metastasis. A chest radiograph showed a small mass in the left upper lobe. A chest CT scan confirmed the presence of a 2 cm mass in the left upper lobe adjacent to the aortic arch which was thought most likely to represent a primary bronchial carcinoma. A fine needle (22 gauge) aspiration biopsy specimen of the left upper lobe mass was taken percutaneously under CT guidance and revealed adenocarcinoma cells. No pneumothorax was seen on the CT scan performed immediately after the procedure, nor on chest radiographs taken at one and four hours after the procedure. The patient was discharged home the same day, but re-presented 26 hours after the lung biopsy with a sudden onset of left chest pain associated with minor exertional dyspnoea. A chest radiograph at this time showed a moderate left pneumothorax which was aspirated with good effect. Over the subsequent months she received symptomatic benefit from cranial radiotherapy, dexamethasone, and anticonvulsants but progressively deteriorated and died 10 months after the start of her illness.

CASE 2
A 68 year old male smoker presented with a one week history of intermittent claudication of his right leg. A chest radiograph performed as part of his routine assessment showed enlarged right paratracheal nodes and a 3 cm lobulated mass in the right upper lobe. A chest CT scan confirmed the presence of a mass within the anterior segment of the right upper lobe and large volume mediastinal and right hilar lymphadenopathy. Bronchoscopic examination was normal and cytological examination of bronchial brushings and washings did not show malignant cells. CT guided percutaneous fine needle (22 gauge) aspiration biopsy of the mass revealed small cell lung carcinoma. A CT scan taken after the procedure did not show a pneumothorax, neither did chest radiographs taken at one and four hours after the biopsy. He was discharged home the same day. Approximately 36 hours after the biopsy he became acutely breathless but did not seek medical attention. His dyspnoea improved over the next 48 hours but then worsened and he was re-admitted four days after the biopsy. A chest radiograph showed a right pneumothorax which was successfully managed by intercostal chest drain insertion. He is currently well and undergoing chemotherapy.

Discussion
Radiologically guided percutaneous fine needle aspiration biopsy is a well established technique in the diagnosis of lung lesions. Sensitivities in the detection of malignancy in excess of 90% are repeatedly obtained.2,3 It is routinely performed as an outpatient procedure.5 Pneumothorax is the most common and potentially serious complication. Rates of pneumothorax of about 25% are common6,7 although most do not require treatment. In a study of 673 patients in whom transthoracic fine needle aspiration biopsy was performed Perlmutter and colleagues6 did not have a single case of pneumothorax occurring more than four hours after the procedure. They recommended that a chest radiograph should be taken at one and four hours after such biopsies in outpatients.

In our institution CT guidance is preferred over fluoroscopic guidance in percutaneous transthoracic needle biopsy for those lesions which are poorly seen or considered inaccessible at fluoroscopy and for lesions adjacent to major cardiovascular structures, either hilar or mediastinal. The pneumothorax rate appears to be higher with CT guidance than that commonly reported with fluoroscopy.5 This is likely to be due to the increased time...
that the biopsy needle remains in the lung, although the increased sensitivity of CT scanning compared with chest radiography in the detection of pneumothorax must be contributory. The two patients we describe both had CT scans performed at the level at which the needle crossed the pleural surface immediately after the biopsy. In neither of these was a pneumothorax apparent. Their delayed pneumothoraces were not therefore due to enlargement of an initial pneumothorax not visible on chest radiographs taken one and four hours after the procedure. Although neither of our two patients gave a history of sudden exertion or coughing prior to the onset of symptoms, it may be that their delayed pneumothoraces were secondary to displacement of small pleural blood clots following the biopsy procedure.

Delayed pneumothorax (of more than 24 hours) has been reported as a complication of transbronchial lung biopsy and also of subclavian vein catheterisation. The occurrence of pneumothorax in two patients more than 24 hours after the procedure emphasises the importance of considering this diagnosis even at a delayed stage. Every patient who undergoes this procedure should be warned of the importance of seeking medical attention should they develop increased breathlessness or chest pain after discharge.


Keywords: cibenzoline, neuromuscular blockade, acute respiratory failure, diaphragm paralysis, phrenic nerve stimulation.

A host of drugs can interfere with the conduction of respiratory muscle at several levels including impairment of neuromuscular transmission. The latter can result in life threatening episodes of respiratory failure, particularly in patients with pre-existing myasthenia gravis and other neuromuscular diseases, and in patients with a reduced respiratory reserve or a decreased ability to eliminate drugs.

We report a case of acute respiratory failure with electrophysiological evidence of neuromuscular blockade involving the diaphragm in a patient with chronic renal failure receiving cibenzoline, a class Ic antiarrhythmic agent. This case appears to be the first report of cibenzoline-induced neuromuscular blockade. The initial report of cibenzoline-induced hypoglycaemia mentions the association of bradycardia, central nervous system depression, and respiratory distress but no details are given.

Case report

CLINICAL HISTORY

The patient was a 75 year old man with end stage chronic renal failure from polycystic renal disease, undergoing continuous ambulatory peritoneal dialysis (CAPD) and receiving oral

Neuromuscular blockade with acute respiratory failure in a patient receiving cibenzoline

Thomas Similowski, Christian Straus, Valérie Attali, Frédéric Girard, François Philippe, Gilbert Deray, Daniel Thomas, Jean-Philippe Derenne

Abstract

Cibenzoline is a class Ic antiarrhythmic agent that can be used to treat supraventricular arrhythmias. A case is reported of cibenzoline overdose in a patient with impaired renal function, leading not only to the usual cardiac and metabolic symptoms (bradycardia and hypoglycaemia), but also to a myastheniform syndrome with acute respiratory failure. Neuromuscular blockade was demonstrated by repetitive supramaximal stimulation of the median nerve, and diaphragmatic involvement was evidenced by applying the same protocol to the phrenic nerve. Muscle strength recovered as serum cibenzoline levels decreased, allowing the patient to be weaned from the ventilator. This observation suggests that cibenzoline, like other antiarrhythmic agents, can be responsible for neuromuscular blockade, and should therefore be used with caution in patients with neuromuscular and respiratory diseases or with impaired renal function.

(Torax 1997;52:582–584)
Cibenzoline-induced diaphragmatic neuromuscular blockade

From day 7 to day 9 the patient remained weak. A marked decrease in the peak-to-peak amplitude of the response observed in the two conditions of stimulation, strongly suggesting neurotransmission failure.

In both muscles the response to a single stimulus was normal in shape and latency (phrenic nerve conduction time 7.1 ms), but a significant decrement in amplitude occurred after stimulation at 4 Hz (58% and 24% for the diaphragm and APB, respectively; fig 1). Single shock-induced action potentials returned to their original amplitude a few seconds after discontinuing the sustained stimulation.

Figure 1 Examples of action potentials of the right diaphragm and abductor pollicis brevis muscle in response to supramaximal transcutaneous stimulation of the right phrenic and median nerves, respectively. The left tracings correspond to an isolated single shock and the right tracings were obtained following several repeated shocks delivered at a frequency of 4 Hz. There was a marked decrease in the peak-to-peak amplitude of the response observed in the two conditions of stimulation, strongly suggesting neurotransmission failure.

**Discussion**

**Diagnosis of neuromuscular blockade and of diaphragmatic involvement**

The clinical picture observed during the first 24 hours in the respiratory intensive care unit was highly suggestive of impaired neuromuscular transmission. A test with an acetylcholinesterase inhibitor could have supported the diagnosis further. However, in the context of an underlying supraventricular arrhythmia in an elderly patient and of cibenzoline-induced bradycardia, cardiac risks potentially associated with edrophonium chloride (Tensilon) or propranolol were considered too important, particularly since a negative test would not have ruled out neuromuscular blockade. Furthermore, the pattern of response to a standard electrophysiological detection protocol accorded well with the diagnosis (fig 1).
Dysfunction of the respiratory muscles in situations where neuromuscular transmission is impaired is a well known fact, but is generally diagnosed solely on the basis of clinical features. To our knowledge, only one study by Mier et al. has specifically examined electrophysiological signs of diaphragmatic neuromuscular blockade; patients with myasthenia gravis, but not controls, exhibited a marked reduction in diaphragm action potentials with sustained phrenic stimulation. Our observation further supports the view that phrenic nerve stimulation can identify patients with neuromuscular transmission abnormalities who are at risk for respiratory failure. It could be very useful in the setting of drug induced neuromuscular disorders that often raise difficult diagnostic questions such as during recovery from anaesthesia.

ROLE OF CIBENZOLINE
Cibenzoline is a class Ic anti-arrhythmic agent with limited class III and class IV activity, which is pharmacologically close to quinidine. It is principally used in France and is not available in all countries.

Class Ic anti-arrhythmic agents interact with neuromuscular transmission at the presynaptic and post-synaptic levels and accidents similar to the one described here have been reported with procainamide and quinidine. These substances can exacerbate myasthenia gravis or are responsible for myasthenia-like syndromes, with such typical features as generalised muscle weakness and bilateral ptosis, both of which were present in our patient. They have also been associated with acute myositis and signs suggestive of anticholinesterase poisoning. Fasciculations and a transient increase in the serum levels of creatine phosphokinase (617 and 1445 U/ml on days 7 and 8, respectively) suggest that this occurred to some degree in the present case.

There is no absolute proof that cibenzoline was responsible for the patient’s respiratory failure. Indeed, because of the severity of the initial episode it was not considered ethical to propose a rechallenge, especially since it appeared likely that the neuromuscular blockade was caused by the very high serum levels of cibenzoline resulting from modified pharmacokinetics in renal insufficiency; a rechallenge at small doses that would not have resulted in relapse of neuromuscular blockade would not mandatorily have been conclusive. However, there are several reasons to suggest that cibenzoline was responsible for the respiratory failure. Firstly, the patient had no underlying disease other than chronic renal failure. The latter can be associated with phrenic nerve dysfunction, but the normal phrenic nerve latency and the absence of marked variations in renal function during the course of the episode argue against a significant contribution of chronic renal failure-associated phrenic nerve lesions to the respiratory disorders. The hypothesis of myasthenia gravis revealed by the acute episode and spontaneously resolving with time could also be raised. The rapid disappearance of myasthenic elements seems to argue against it, as does the absence of residual muscle weakness after six months. This hypothesis would not account for the elements that suggest associated myositis and an anticholinesterase-like effect – namely, increased serum levels of creatine phosphokinase and fasciculations, respectively. Secondly, the recovery of diaphragm strength closely paralleled the fall in serum levels of cibenzoline. Thirdly, the patient received only cibenzoline and nifedipine at the time of respiratory failure. Nifedipine, which he had already received for several years, is not a likely candidate as the source of neuromuscular blockade but consideration must be given to its possible role in promoting or potentiating it. Indeed, the diaphragm may be particularly sensitive to the deleterious myoneural effects of calcium channel blockers because excitation-contraction coupling in this muscle is dependent on extracellular calcium. Although there do not seem to be data available to establish a dose-response relationship for undesirable events associated with cibenzoline, such a potentiation could explain an apparent discrepancy between the serum level of cibenzoline (more than twice the upper limit of the normal range) and the magnitude of the observed effect on neuromuscular transmission.

In conclusion, our observation seems to confirm that drugs, or a combination of drugs, that possibly interfere with neuromuscular transmission can be a source of serious respiratory disorders, not only in patients with underlying neuromuscular or respiratory diseases but also in patients with a normal respiratory system who have impaired ability to eliminate drugs.
Delayed pneumothorax after CT-guided percutaneous fine needle aspiration lung biopsy.

Z C Traill and F V Gleeson

Thorax 1997 52: 581-582
doi: 10.1136/thx.52.6.581

Updated information and services can be found at:
http://thorax.bmj.com/content/52/6/581

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/